Diclofenac reduces the use of antibiotics in women with uncomplicated lower urinary tract infection (UTI) but remains less effective than norfloxacin for symptom relief of UTI, according to a recent study. In addition, diclofenac appears to be associated with an elevated risk of pyelonephritis.
Use of the blood infection biomarker procalcitonin as a guide to prescribing antibiotics led to lower antibiotic exposure and side effects, as well as a lower mortality rate in individuals with acute respiratory infections, based on findings of a meta-analysis.
The paediatric dosing of intravenous zanamivir has a safety profile that is consistent with that expected in a population of children hospitalized for severe or progressive influenza, with majority achieving clinical improvement during the treatment course, according to a study.
Treatment with a ribavirin-free regimen of coformulated glecaprevir plus pibrentasvir appears to yield a high rate of sustained virologic response in hepatitis C virus-infected patients with advanced chronic kidney disease, while having an acceptable safety profile, according to the EXPEDITION-4 trial.
Patients with acute-on-chronic liver failure (ACLF) who fulfil both APASL* and EASL** criteria have an elevated risk of liver disease-related mortality, according to a retrospective single-centre study conducted in Singapore. The findings also revealed the factors associated with a poorer prognosis.
New drug applications approved by US FDA as of 1 - 15 November 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In patients infected with Helicobacter pylori, long-term use of proton pump inhibitors is associated with an increased risk of gastric cancer even after treatment for the infection, a recent population-based study has shown.
The risks of hepatocellular carcinoma (HCC) and death/transplantation in chronic hepatitis B virus infection appear to be greater in untreated immune-tolerant-phase patients than in treated immune-active-phase patients, a study has found.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In patients with underlying heart failure (HF) or chronic obstructive pulmonary disease (COPD), concurrent episodes of community-acquired pneumonia increase the risk of disease exacerbations, such as short-term cardiac complications and respiratory failure, a recent study has shown.
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coliand Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6